DoJ Targets Device Labeling Accuracy In $300 Million Quest Settlement
This article was originally published in The Gray Sheet
Executive Summary
A $302 million settlement between Quest Diagnostics and the Department of Justice announced April 15 suggests DoJ will go after device firms for knowingly misrepresenting product information in labeling and marketing materials, even if FDA is not actively investigating the matter